Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2018

01-12-2018 | Preclinical study

Labour productivity loss caused by premature deaths associated with breast cancer: results from Spain over a 10-year period

Authors: J. Oliva-Moreno, L. M. Peña-Longobardo

Published in: Breast Cancer Research and Treatment | Issue 3/2018

Login to get access

Abstract

Background

Breast cancer is one of the most common cancers among women worldwide, and is the most common cause of cancer deaths in them. Given that such disease has a significant impact on middle-aged women, it can result in considerable labour productivity losses. The main objective of this study is therefore to analyse labour productivity losses and years of potential working life lost as a result of premature deaths from breast cancer in Spain over a 10-year period (2005–2014).

Method

To this end, by combining data on average salary (Salary Structure Survey), occupation (Active Population Survey) and deaths (death registration according to cause of death), a simulation model based on the human capital approach was constructed to estimate productivity losses associated with premature deaths caused by this disease.

Results

The results reveal that labour productivity losses in women are estimated to cost 2,137 million euros, as a result of the 22,716 deaths occurring during working age and the 292,848 years of potential productive life lost. This implies that breast cancer is responsible for 10.45% of all estimated female labour productivity losses caused by premature deaths in the reference year.

Conclusion

The article concludes by highlighting the major economic impact associated with breast cancer deaths and by pointing out future research areas.
Literature
2.
go back to reference Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C et al (2015) The global burden of cancer 2013. JAMA Oncol 1(4):505–527CrossRef Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C et al (2015) The global burden of cancer 2013. JAMA Oncol 1(4):505–527CrossRef
3.
go back to reference Cabanes A, Vidal E, Aragonés N, Pérez-Gómez B, Pollán M, Lope V, López-Abente G (2010) Cancer mortality trends in Spain: 1980–2007. Ann Oncol 21(Suppl 3):iii14–i20PubMed Cabanes A, Vidal E, Aragonés N, Pérez-Gómez B, Pollán M, Lope V, López-Abente G (2010) Cancer mortality trends in Spain: 1980–2007. Ann Oncol 21(Suppl 3):iii14–i20PubMed
4.
go back to reference Broekx S, Den Hond E, Torfs R, Remacle A, Mertens R, D’Hooghe T, Neven P, Christiaens MR, Simoens S (2011) The costs of breast cancer prior to and following diagnosis. Eur J Health Econ 12(4):311–317CrossRef Broekx S, Den Hond E, Torfs R, Remacle A, Mertens R, D’Hooghe T, Neven P, Christiaens MR, Simoens S (2011) The costs of breast cancer prior to and following diagnosis. Eur J Health Econ 12(4):311–317CrossRef
5.
go back to reference Mujahid MS, Janz NK, Hawley ST, Griggs JJ, Hamilton AS, Katz SJ (2010) The impact of sociodemographic, treatment, and work support on missed work after breast cancer diagnosis. Breast Cancer Res Treat 119(1):213–220CrossRef Mujahid MS, Janz NK, Hawley ST, Griggs JJ, Hamilton AS, Katz SJ (2010) The impact of sociodemographic, treatment, and work support on missed work after breast cancer diagnosis. Breast Cancer Res Treat 119(1):213–220CrossRef
6.
go back to reference Drolet M, Maunsell E, Mondor M, Brisson C, Brisson J, Mâsse B, Deschênes L (2005) Work absence after breast cancer diagnosis: a population-based study. CMAJ 27(7):765–771 173(CrossRef Drolet M, Maunsell E, Mondor M, Brisson C, Brisson J, Mâsse B, Deschênes L (2005) Work absence after breast cancer diagnosis: a population-based study. CMAJ 27(7):765–771 173(CrossRef
7.
go back to reference Luengo-Fernandez R, Leal J, Gray A, Sullivan R (2013) Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 14(12):1165–1174CrossRef Luengo-Fernandez R, Leal J, Gray A, Sullivan R (2013) Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 14(12):1165–1174CrossRef
8.
go back to reference Oliva-Moreno J (2012) Loss of labour productivity caused by disease and health problems: what is the magnitude of its effect on Spain’s Economy? Eur J Health Econ 13(5):605–614CrossRef Oliva-Moreno J (2012) Loss of labour productivity caused by disease and health problems: what is the magnitude of its effect on Spain’s Economy? Eur J Health Econ 13(5):605–614CrossRef
9.
go back to reference Grossman M (1972) The demand for health: a theoretical and empirical investigation. Columbia University Press, New York Grossman M (1972) The demand for health: a theoretical and empirical investigation. Columbia University Press, New York
10.
go back to reference Grossman M ( 2000) The human capital model of the demand for health. In: Culyer AJ, Newhouse JP (eds.). Handbook of health economics. Elsevier, Boston. Grossman M ( 2000) The human capital model of the demand for health. In: Culyer AJ, Newhouse JP (eds.). Handbook of health economics. Elsevier, Boston.
15.
go back to reference López-Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, Puig-Junoy J (2010) Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ 11(5):513–520CrossRef López-Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, Puig-Junoy J (2010) Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ 11(5):513–520CrossRef
17.
go back to reference Hanly PA, Sharp L (2014) The cost of lost productivity due to premature cancer-related mortality: an economic measure of the cancer burden. BMC Cancer 14:224CrossRef Hanly PA, Sharp L (2014) The cost of lost productivity due to premature cancer-related mortality: an economic measure of the cancer burden. BMC Cancer 14:224CrossRef
18.
go back to reference Hanly A, Soerjomataram I, Sharp L (2015) Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in Europe. Int J Cancer 136(4):E136–E145CrossRef Hanly A, Soerjomataram I, Sharp L (2015) Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in Europe. Int J Cancer 136(4):E136–E145CrossRef
19.
go back to reference Bradley CJ, Bednarek HL, Neumark D (2002) Breast cancer survival, work, and earnings. J Health Econ 21(5):757–779CrossRef Bradley CJ, Bednarek HL, Neumark D (2002) Breast cancer survival, work, and earnings. J Health Econ 21(5):757–779CrossRef
20.
go back to reference Bradley CJ, Yabroff KR, Dahman B, Feuer EJ, Mariotto A, Brown ML (2008) Productivity costs of cancer mortality in the United States: 2000–2020. J Natl Cancer Inst 17(24):1763–1770 100(CrossRef Bradley CJ, Yabroff KR, Dahman B, Feuer EJ, Mariotto A, Brown ML (2008) Productivity costs of cancer mortality in the United States: 2000–2020. J Natl Cancer Inst 17(24):1763–1770 100(CrossRef
21.
go back to reference Max W, Sung HY, Stark B (2009) The economic burden of breast cancer in California. Breast Cancer Res Treat 116(1):201–207CrossRef Max W, Sung HY, Stark B (2009) The economic burden of breast cancer in California. Breast Cancer Res Treat 116(1):201–207CrossRef
23.
go back to reference Zheng Z, Yabroff KR, Guy GP Jr, Han X, Li C, Banegas MP, Ekwueme DU, Jemal A: Annual Medical Expenditure and Productivity Loss Among Colorectal, Female Breast, and Prostate Cancer Survivors in the United States. JNCI J Natl Cancer Inst. 2016; 108(5)CrossRef Zheng Z, Yabroff KR, Guy GP Jr, Han X, Li C, Banegas MP, Ekwueme DU, Jemal A: Annual Medical Expenditure and Productivity Loss Among Colorectal, Female Breast, and Prostate Cancer Survivors in the United States. JNCI J Natl Cancer Inst. 2016; 108(5)CrossRef
24.
go back to reference Hanly P, Timmons A, Walsh PM, Sharp L (2012) Breast and prostate cancer productivity costs: a comparison of the human capital approach and the friction cost approach. Value Health 15(3):429–436CrossRef Hanly P, Timmons A, Walsh PM, Sharp L (2012) Breast and prostate cancer productivity costs: a comparison of the human capital approach and the friction cost approach. Value Health 15(3):429–436CrossRef
25.
go back to reference Ekwueme DU, Guy GP Jr, Rim SH, White A, Hall IJ, Fairley TL, Dean HD (2014) Health and economic impact of breast cancer mortality in young women, 1970–2008. Am J Prev Med 46(1):71–79CrossRef Ekwueme DU, Guy GP Jr, Rim SH, White A, Hall IJ, Fairley TL, Dean HD (2014) Health and economic impact of breast cancer mortality in young women, 1970–2008. Am J Prev Med 46(1):71–79CrossRef
26.
go back to reference Łyszczarz B, Nojszewska E (2017) Productivity losses and public finance burden attributable to breast cancer in Poland, 2010–2014. BMC Cancer 17(1):676CrossRef Łyszczarz B, Nojszewska E (2017) Productivity losses and public finance burden attributable to breast cancer in Poland, 2010–2014. BMC Cancer 17(1):676CrossRef
27.
go back to reference Carter HE, Schofield DJ, Shrestha R: The Productivity Costs of Premature Mortality Due to Cancer in Australia: Evidence from a Microsimulation Model. PLoS ONE. 2016; 11(12)CrossRef Carter HE, Schofield DJ, Shrestha R: The Productivity Costs of Premature Mortality Due to Cancer in Australia: Evidence from a Microsimulation Model. PLoS ONE. 2016; 11(12)CrossRef
28.
go back to reference Pearce A, Bradley C, Hanly P, O’Neill C, Thomas AA, Molcho M, Sharp L (2016) Projecting productivity losses for cancer-related mortality 2011–2030. BMC Cancer 16(1):804CrossRef Pearce A, Bradley C, Hanly P, O’Neill C, Thomas AA, Molcho M, Sharp L (2016) Projecting productivity losses for cancer-related mortality 2011–2030. BMC Cancer 16(1):804CrossRef
29.
go back to reference Oliva J, Lobo F, López-Bastida J, Zozaya N, Romay R (2005) Indirect costs of cervical and breast cancers in Spain. Eur J Health Econ 6(4):309–313CrossRef Oliva J, Lobo F, López-Bastida J, Zozaya N, Romay R (2005) Indirect costs of cervical and breast cancers in Spain. Eur J Health Econ 6(4):309–313CrossRef
30.
go back to reference Peña-Longobardo LM, Aranda-Reneo I, Oliva-Moreno J, Val-Castello J (2015) Pérdidas laborales ocasionadas por muertes prematuras en España: Un análisis para el periodo 2005–2009. Rev Esp Salud Pública 89:39–50CrossRef Peña-Longobardo LM, Aranda-Reneo I, Oliva-Moreno J, Val-Castello J (2015) Pérdidas laborales ocasionadas por muertes prematuras en España: Un análisis para el periodo 2005–2009. Rev Esp Salud Pública 89:39–50CrossRef
31.
go back to reference Vicente-Herrero MT, Terradillos-García MJ, Ramírez-Iñiguez de la Torre, MV, Capdevila-García LM, Aguilar-Jiménez E, López-González AA (2012) El cáncer de mama en España. Aproximación a su coste económico por incapacidad temporal durante 2010. GAMO 11:351–357 Vicente-Herrero MT, Terradillos-García MJ, Ramírez-Iñiguez de la Torre, MV, Capdevila-García LM, Aguilar-Jiménez E, López-González AA (2012) El cáncer de mama en España. Aproximación a su coste económico por incapacidad temporal durante 2010. GAMO 11:351–357
32.
go back to reference Lidgren M, Wilking N, Jönsson B, Rehnberg C (2007) Resource use and costs associated with different states of breast cancer. Int J Technol Assess Health Care 23(2):223–231CrossRef Lidgren M, Wilking N, Jönsson B, Rehnberg C (2007) Resource use and costs associated with different states of breast cancer. Int J Technol Assess Health Care 23(2):223–231CrossRef
33.
go back to reference Yabroff KR, Kim Y (2009) Time costs associated with informal caregiving for cancer survivors. Cancer 115(18):4362–4373CrossRef Yabroff KR, Kim Y (2009) Time costs associated with informal caregiving for cancer survivors. Cancer 115(18):4362–4373CrossRef
34.
go back to reference Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA (2016) Economic Burden of Bladder Cancer Across the European Union. Eur Urol 69(3):438–447 (2016)CrossRef Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA (2016) Economic Burden of Bladder Cancer Across the European Union. Eur Urol 69(3):438–447 (2016)CrossRef
35.
go back to reference Round J, Jones L, Morris S (2015) Estimating the cost of caring for people with cancer at the end of life: A modelling study. Palliat Med 29(10):899–907CrossRef Round J, Jones L, Morris S (2015) Estimating the cost of caring for people with cancer at the end of life: A modelling study. Palliat Med 29(10):899–907CrossRef
36.
go back to reference Liljas B (1998) How to calculate indirect costs in economic evaluations. Pharmacoeconomics 13:1–7CrossRef Liljas B (1998) How to calculate indirect costs in economic evaluations. Pharmacoeconomics 13:1–7CrossRef
37.
go back to reference Krol M, Brouwer W, Rutten F (2013) Productivity costs in economic evaluations: past, present, future. Pharmacoeconomics 31(7):537–549CrossRef Krol M, Brouwer W, Rutten F (2013) Productivity costs in economic evaluations: past, present, future. Pharmacoeconomics 31(7):537–549CrossRef
38.
go back to reference Krol M, Brouwer W (2014) How to estimate productivity costs in economic evaluations. Pharmacoeconomics 32(4):335–344CrossRef Krol M, Brouwer W (2014) How to estimate productivity costs in economic evaluations. Pharmacoeconomics 32(4):335–344CrossRef
39.
go back to reference Hanly P, Pearce A, Sharp L (2014) The cost of premature cancer-related mortality: a review and assessment of the evidence. Expert Rev Pharmacoecon Outcomes Res 14(3):355–377CrossRef Hanly P, Pearce A, Sharp L (2014) The cost of premature cancer-related mortality: a review and assessment of the evidence. Expert Rev Pharmacoecon Outcomes Res 14(3):355–377CrossRef
40.
go back to reference Koopmanschap MA, van Ineveld BM (1992) Towards a new approach for estimating indirect costs of disease. Soc Sci Med 34:1005–1010CrossRef Koopmanschap MA, van Ineveld BM (1992) Towards a new approach for estimating indirect costs of disease. Soc Sci Med 34:1005–1010CrossRef
Metadata
Title
Labour productivity loss caused by premature deaths associated with breast cancer: results from Spain over a 10-year period
Authors
J. Oliva-Moreno
L. M. Peña-Longobardo
Publication date
01-12-2018
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4963-z

Other articles of this Issue 3/2018

Breast Cancer Research and Treatment 3/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine